What is Lifesci Capital’s Forecast for ELDN FY2024 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at Lifesci Capital boosted their FY2024 earnings per share estimates for Eledon Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($1.35) for the year, up from their previous estimate of ($1.47). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($1.52) per share. Lifesci Capital also issued estimates for Eledon Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS.

Eledon Pharmaceuticals Stock Performance

Shares of ELDN opened at $4.00 on Friday. The stock has a market capitalization of $158.62 million, a PE ratio of -1.99 and a beta of 0.76. The company has a 50 day moving average price of $3.26 and a 200-day moving average price of $2.89. Eledon Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Institutional Trading of Eledon Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ELDN. Vanguard Group Inc. raised its position in shares of Eledon Pharmaceuticals by 39.4% in the 1st quarter. Vanguard Group Inc. now owns 969,121 shares of the company’s stock worth $1,996,000 after acquiring an additional 273,703 shares in the last quarter. CM Management LLC grew its stake in Eledon Pharmaceuticals by 14.3% in the first quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $330,000 after purchasing an additional 20,000 shares during the last quarter. Marco Investment Management LLC raised its holdings in Eledon Pharmaceuticals by 22.3% in the second quarter. Marco Investment Management LLC now owns 30,344 shares of the company’s stock worth $80,000 after purchasing an additional 5,535 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Eledon Pharmaceuticals during the second quarter valued at about $80,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Eledon Pharmaceuticals by 57.1% in the 2nd quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after buying an additional 49,704 shares in the last quarter. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).